Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer (NSCLC) at first interim analysis (99 events; median brigatinib follow-up, 11.0 months) in the open-label, phase III ALTA-1L trial (ClinicalTrials.gov identifier: NCT02737501). We report results of the second prespecified interim analysis (150 events). Brigatinib represents a once-daily ALK inhibitor with superior efficacy, tolerability, and QoL over crizotinib, making it a promising first-line treatment of ALK-positive NSCLC. READ ARTICLE
Journal of Clinical Oncology DOI:10.1200/JCO.20.00505
Authors: D. Ross Camidge, Dong-Wan Kim, Marcello Tiseo, Corey J. Langer, Myung-Ju Ahn,
Alice T. Shaw, Rudolf M. Huber, Maximilian J. Hochmair, Dae Ho Lee,
Lyudmila A. Bazhenova, Kathryn A. Gold, Sai-Hong Ignatius Ou, Howard L. West,
William Reichmann, Jeff Haney, Tim Clackson, David Kerstein, and Scott N. Gettinger
